drugset / Trial / NCT00877903

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

NCT00877903

Phase 2 Completed 220 enrolled Mesoblast, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the present study is to establish the safety and efficacy of Prochymal® following first acute myocardial infarction.

Timeline

Start
2009-03-30
Primary completion
2011-05-18
Completion
2016-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Prochymal® Cell therapy 2e+08 cells Intravenous

Indications